MétaCan
Menu
Back to cohort
Record W4405467030 · doi:10.1016/s1473-3099(24)00665-0

Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis

2024· article· en· W4405467030 on OpenAlexafffund
Julia C. Bennett, Maria Deloria Knoll, E. Wangeci Kagucia, Maria Garcia Quesada, Scott L. Zeger, Marissa K. Hetrich, Yangyupei Yang, Carly Herbert, Anju Ogyu, Adam L. Cohen, İnci Yıldırım, Brita Askeland Winje, Anne von Gottberg, Delphine Viriot, Mark van der Linden, Palle Valentiner‐Branth, Shigeru Suga, Anneke Steens, Anna Skoczyńska, Nadja Sinkovec Zorko, J. Anthony G. Scott, Camelia Savulescu, Larisa Savrasova, Juan Carlos Sanz, Fiona M. Russell, Leah J. Ricketson, Rodrigo Puentes, J. Pekka Nuorti, Jolita Mereckiene, Kimberley McMahon, Allison McGeer, Lucia Mad'arová, Grant Mackenzie, Laura MacDonald, Tiia Lepp, Shamez Ladhani, Karl G. Kristinsson, Jana Kozáková, Nicola P. Klein, Sanjay Jayasinghe, Pak‐Leung Ho, Markus Hilty, Robert S. Heyderman, Md Hasanuzzaman, Laura L. Hammitt, Marcela Guevara, Marta Grgič-Vitek, Ryan Gierke, Theano Georgakopoulou, Yvonne Galloway, Idrissa Diawara, Stefanie Desmet, Philippe De Wals, Ron Dagan, Edoardo Colzani, Cheryl Cohen, Pilar Ciruela, Urtnasan Chuluunbat, Guanhao Chan, Romina Camilli, Michael G. Bruce, Maria-Cristina C Brandileone, Godfrey Bigogo, Krow Ampofo, Katherine L. O’Brien, Daniel R. Feikin, Kyla Hayford

Bibliographic record

VenueThe Lancet Infectious Diseases · 2024
Typearticle
Languageen
FieldMedicine
TopicPneumonia and Respiratory Infections
Canadian institutionsUniversité LavalUniversity Health NetworkUniversity of Calgary
FundersFaculty of Medicine and Health, University of SydneyNational Institute of Allergy and Infectious DiseasesMedical Research CouncilKU LeuvenInstitute of Environmental Science and ResearchUniversity of Hong KongUniversity College LondonNational Institute for Health and Care ResearchNovavaxWellcome TrustSanofi PasteurRegeneron PharmaceuticalsQueen Mary University of LondonPfizer CanadaBioFire DiagnosticsUniversité LavalSanofiUniversity of BernWorld Health OrganizationBill and Melinda Gates FoundationPfizer
KeywordsPneumococcal diseaseMedicinePneumococcal infectionsPneumococcal conjugate vaccineVirologyStreptococcus pneumoniaeConjugateImmunologyMicrobiologyBiologyAntibiotics

Abstract

fetched live from OpenAlex

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages. METHODS: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%. Annual incidence rate ratios (IRRs) were estimated comparing the incidence before any PCV with each year post-PCV10 or post-PCV13 introduction using Bayesian multi-level, mixed-effects Poisson regressions, by site and age group. All site-weighted average IRRs were estimated using linear mixed-effects regression, stratified by product and previous seven-valent PCV (PCV7) effect (none, moderate, or substantial). FINDINGS: Analyses included 32 PCV13 sites (488 758 cases) and 15 PCV10 sites (46 386 cases) in 30 countries, primarily high income (39 sites), using booster dose schedules (41 sites). By 6 years after PCV10 or PCV13 introduction, IPD due to PCV10-type serotypes and PCV10-related serotype 6A declined substantially for both products (age <5 years: 83-99% decline; ≥65 years: 54-96% decline). PCV7-related serotype 19A increases before PCV10 or PCV13 introduction were reversed at PCV13 sites (age <5 years: 61-79% decline relative to before any PCV; age ≥65 years: 7-26% decline) but increased at PCV10 sites (age <5 years: 1·6-2·3-fold; age ≥65 years: 3·6-4·9-fold). Serotype 3 IRRs had no consistent trends for either product or age group. Non-PCV13-type IPD increased similarly for both products (age <5 years: 2·3-3·3-fold; age ≥65 years: 1·7-2·3-fold). Despite different serotype 19A trends, all-serotype IPD declined similarly between products among children younger than 5 years (58-74%); among adults aged 65 years or older, declines were greater at PCV13 (25-29%) than PCV10 (4-14%) sites, but other differences between sites precluded attribution to product. INTERPRETATION: Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotype 19A increases at PCV10 sites and declines at PCV13 sites suggest that PCV13 use would further reduce IPD at PCV10 sites. FUNDING: Bill & Melinda Gates Foundation as part of the WHO Pneumococcal Vaccines Technical Coordination Project.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.924

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.348
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations60
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueThe Lancet Infectious DiseasesSame topicPneumonia and Respiratory InfectionsFrench-language works237,207